This is a very early clinical milestone with no efficacy data. The absence of RTGel in the current formulation means the Phase 1 results may not reflect the potential of the RTGel-formulated version. Monitor for safety and tolerability readouts and any updates on the RTGel formulation studies.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 2 $34.36entry
- T+1 · 14d ago +0.12%α −0.18% · $34.40
- T+5 · 8d ago −23.43%α −23.51% · $26.31
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
UroGen Pharma announced the first patient dosed in a Phase 1 trial of UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial evaluates safety, tolerability, and pharmacokinetics of intravesical administration. This is an early-stage clinical milestone with no efficacy data yet, and the formulation being tested does not use UroGen's proprietary RTGel technology.
Key Facts
- First patient dosed in Phase 1, open-label, dose-escalation trial of UGN-501 for NMIBC.
- UGN-501 is an investigational next-generation oncolytic virus designed for direct tumor cell destruction and anti-tumor immune activation.
- The Phase 1 trial will determine the recommended Phase 2 dose in adults with recurrent NMIBC (high-grade Ta/T1, CIS, or low-grade Ta/T1).
- The formulation in this Phase 1 trial is aqueous and does not contain UroGen's proprietary RTGel technology.
- Parallel nonclinical studies are exploring UGN-501 formulated with RTGel.
- Trial design: six once-weekly instillations over 12 weeks; maintenance for responders (three weekly instillations quarterly from month 3 to month 12).
Financial Impact
No financial data disclosed; early clinical milestone with no revenue impact expected for years.
Risk Factors
- Phase 1 trial is early-stage; safety or efficacy issues could halt development.
- The current formulation does not use RTGel, which may limit therapeutic potential versus the RTGel version.
- NMIBC is a competitive space with multiple approved therapies; UGN-501 must differentiate to succeed.
- Forward-looking statements carry risks of clinical failure, regulatory hurdles, and need for additional capital.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3393063 |
Track record
16 reports on URGN
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +54.89% at T+60 after the Mar 2, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $25.90 Now $28.10 +8.49% settles Nov 23
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bearish 6/10 Entry $28.74 to $26.10 Now $28.10 +2.23% ▲ +9.19% +8.27% vs SPY
- Nov 2, 202614d ago Press Release Neutral 4/10 Viewing Entry $34.36 to $26.31 Now $28.10 −18.22% ▼ −23.43% −23.51% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $33.75 to $28.74 Now $28.10 −16.74% ▼ −14.84% −14.13% vs SPY
- Oct 19, 202628d ago Press Release Bullish 6/10 Entry $34.15 to $34.23 Now $28.10 −17.72% ▲ +0.23% +0.38% vs SPY
- Oct 9, 20265w ago 144 Neutral 2/10 Entry $36.83 to $34.56 Now $28.10 −23.70% ▼ −6.16% −4.20% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $45.00 to $43.04 Now $28.10 −37.56% ▼ −4.36% −4.02% vs SPY
- Aug 20, 202612w ago 8-K Neutral 4/10 Entry $46.80 to $45.50 Now $28.10 −39.96% ▼ −2.78% −3.89% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $46.43 to $49.00 Now $28.10 −39.48% ▲ +5.54% +5.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers